Medtronic Agrees To Settle Infuse Shareholder Suit
Executive Summary
Device manufacturer Medtronic has offered to pay $43m to resolve a lawsuit brought by shareholders. The suit, filed in 2013, claimed that the company defrauded investors via deceptive marketing for its Infuse bone graft product.
You may also be interested in...
Medtronic Announces End To Shareholder Infuse Case
A long-running shareholder case against Medtronic has come to an end after the US Supreme Court refused to hear the plaintiff's appeal.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
FDA Leader Looks To International Effort On Pediatric Device Development
Collaboration with Japan and Europe could help ease the development path for pediatric devices, cardiovascular device office director Bram Zuckerman said at a recent conference. Zuckerman also spoke on other cardiac device priorities at the FDA.